The management of unresectable hepatocellular carcinoma (HCC) involves recognizing and managing adverse events and effectively working with a multidisciplinary team. This Clinical ForumSM brings together an interventional radiologist, oncologist, and hepatologist to discuss how they work together at their institutions to achieve a common goal.
This activity is designed to engage your critical thinking and challenge suboptimal approaches to patient care. It features videos of 2 patients with chronic urticaria (CU) and challenging interactive questions related to their histories and treatments. You will have an opportunity to hear the patients’ perspectives of CU, and learn from our expert faculty.
In this educational activity, which is based on a symposium held during the American Psychiatric Nurses Association 17th Annual Clinical Psychopharmacology Institute meeting, you will hear from a live adolescent patient with bipolar disorder and her caregiver, as well as 2 faculty experts. You will have an opportunity to learn more about the diagnosis and treatment for pediatric and adolescent bipolar disorder through challenging clinical case presentations, clinical questions, and a panel discussion highlighting the personal impact of bipolar disorder.
This conversation-centered activity with educational pearls takes learners through a clinical exchange between patients with multiple sclerosis and their providers.
The successful management of nontuberculous mycobacteria lung disease (NTM-LD) remains challenging owing to the need for long-term treatment, the ongoing risks of adverse drug reactions, and the potential for nonadherence. These factors underscore the importance of specialty referral and shared decision making in the successful management of NTM-LD, as Dr. Anne O’Donnell and her patient Brinkley exemplify.
Discover scenarios of patients with multiple sclerosis followed by assessment and management questions that explore how the patients can be managed optimally.
This unique educational initiative harnesses the power of reflection and recognition of suboptimal approaches to patient care to allow you to rethink clinical decisions based on the scenarios presented, and to modify treatment plans accordingly. You can compare your responses to interactive questions with those of your peers and learn from our expert faculty.
Nontuberculous mycobacteria lung disease (NTM-LD) is a relatively uncommon condition, although its prevalence is rising. In this interactive CME activity, Drs. Anne O’Donnell and Patrick Flume review 2 patient cases to demonstrate how clinicians can maintain a greater index of suspicion for the diagnosis of NTM-LD to enable timely and effective therapy. The management of NTM-LD remains challenging, owing to the need for long-term treatment, the potential for drug-related toxicities, and patient nonadherence. These factors underscore the importance of specialty referral for the successful management of NTM-LD.
The panel will delve into topics covering safety/efficacy data for PCSK9 inhibitors (PCSK9-Is), 2018 ACC/AHA guideline updates, and patient selection for treatment intensification with PCSK9-Is. Faculty will examine key matters in patient care, provide illustrative patient case scenarios, pose practical solutions to common issues encountered in clinical practice, and Charles will provide insight into his experience with familial hypercholesterolemia, its treatment, and his interaction with the healthcare system.
Advances in inflammatory bowel disease (IBD) treatment have improved outcomes for many patients but personalizing therapy and predicting response to therapy is a huge challenge. This has led to underutilization of effective regimens, undertreatment, and suboptimal outcomes. This activity reviews how new and emerging clinical decision support tools can help providers bridge this gap by predicting individualized disease complication risk and response to therapy.
With rapidly changing guidelines and treatment indications, it can be difficult discerning when to start a disease-modifying therapy in the early spectrum of multiple sclerosis (MS), such as clinically and radiologically isolated syndrome; how to discuss MS management in women of childbearing age; or how to use the new guidelines to confirm an MS diagnosis. In this supplement, these topics will be addressed along with recognizing treatment failure, knowing when to switch therapies, and how to incorporate patient preference in treatment-related decisions.
This activity is designed to engage your critical thinking about patients who may have alpha-1 antitrypsin deficiency (AATD) and to challenge suboptimal approaches to the management of patients with AATD lung disease. You will hear unique insights from 3 clinical experts and a patient living with AATD during this dynamic presentation.
In this CME activity, you will hear insights from 3 hemophilia experts on the current management approach to hemophilia A with and without inhibitors, new developments in hemophilia A therapies, and ways to incorporate shared decision making when treating patients with hemophilia A. In addition, you will have an opportunity to practice through a series of questions and compare yourself to your peers.
Join leading inflammatory bowel disease (IBD) experts in this interactive activity where you will have the opportunity to follow a patient to learn about the diagnosis and management of IBD. Be sure to check out the Crohn's & Colitis Foundation resources as well as a comprehensive reading list related to the learning objectives following the closing commentary section of the activity.
Join leading inflammatory bowel disease (IBD) experts in this interactive activity where you will have the opportunity to follow a patient to learn about the long-term management and surgery indications of IBD. Be sure to check out the Crohn's & Colitis Foundation resources as well as a comprehensive reading list related to the learning objectives following the closing commentary section of the activity.
This enduring activity will provide learners with the latest developments in immunotherapy for leukemia, lymphoma, and myeloma and how these developments can be incorporated into regimens to improve the outcome of patients with these diseases.